Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. reported that Chief Scientific Officer Alan J. Russell received a grant of stock options for 65,000 shares of common stock on August 12, 2026. An amendment corrects the option’s exercise price to $43.56 per share, reflecting the fair market value on the grant date.

The options have an expiration date of August 12, 2036. According to the vesting terms, 1/48 of the shares vest each month beginning September 12, 2026, contingent on Russell continuing as a service provider through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Russell Alan J

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	65,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 65,000 shares (Direct)

Footnotes (1)

1. F1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Key Figures

Options Granted: 65,000 shares Exercise Price: $43.56 per share Options Following Transaction: 65,000 shares +3 more

6 metrics

Options Granted 65,000 shares Stock Option (Right to Buy) grant on August 12, 2026

Exercise Price $43.56 per share Corrected exercise price reflecting fair market value on grant date

Options Following Transaction 65,000 shares Total derivative shares held after the reported grant

Vesting Rate 1/48 of shares per month Monthly vesting beginning September 12, 2026, subject to service

Vesting Commencement Date September 12, 2026 First monthly vesting date for the stock option grant

Expiration Date August 12, 2036 Expiration of the 65,000-share stock option award

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"The correct exercise price is $43.56, which reflects the fair market value"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48th of the shares subject to the option vest each month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-08-12"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

What insider transaction did EWTX report for Chief Scientific Officer Alan J. Russell?

Edgewise Therapeutics reported a grant of 65,000 stock options to Chief Scientific Officer Alan J. Russell on August 12, 2026. These options relate to common stock and represent a compensation award rather than an open-market purchase or sale of existing shares.

What is the corrected exercise price of the EWTX stock options granted to Alan J. Russell?

The amended filing states the correct exercise price is $43.56 per share. This replaces a previously reported price of $0.00, which the company describes as a clerical or administrative error, and reflects the fair market value on the grant date.

How many EWTX shares are covered by Alan J. Russell’s stock option grant?

The option grant covers 65,000 shares of Edgewise Therapeutics common stock. After the reported grant, the filing shows total derivative holdings from this award at 65,000 options, all subject to the stated vesting and expiration terms.

What are the vesting terms of the EWTX stock options granted to Alan J. Russell?

The options vest in 1/48 monthly installments, starting on September 12, 2026. Vesting continues each month as long as Russell remains a service provider through each vesting date, resulting in full vesting over approximately four years.

When do Alan J. Russell’s EWTX stock options expire?

The stock options granted to Alan J. Russell have an expiration date of August 12, 2036. After that date, any unexercised portion of the 65,000-share option award can no longer be exercised for Edgewise Therapeutics common stock.

Does the Form 4/A for EWTX involve a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed. The document-level field shows the box as unchecked, and there is no footnote stating that this stock option grant was made pursuant to a pre-arranged 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 06:41 PM Accepted by SEC EDGAR 08/17/2026 - 06:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Alan J

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/14/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$43.56	08/12/2026		A		65,000		(1)	08/12/2036	Common Stock	65,000	$0.00	65,000	D

Explanation of Responses:

1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

This amendment corrects the exercise price of the reported option grant, which was reported as $0.00 due to a clerical/administrative error. The correct exercise price is $43.56, which reflects the fair market value of the underlying security on the date of grant.

	/s/ John R. Moore Attorney-in-Fact for Alan J Russell	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)